Juniper Biosciences

What Juniper Biosciences does

Juniper Biosciences is a privately held radiopharmaceutical drug development company founded in 2025 and headquartered in Bridgewater, New Jersey, operating under parent entity Juniper Radiopharma LLC. The company develops targeted cancer diagnostics and therapeutics using radioisotopes paired with high-specificity ligands, combining PET imaging agents with therapeutic radiopharmaceuticals to enable precision oncology applications. Its pipeline centers on JBS-003 (18F-fluoromisonidazole / F-MISO), a first-in-class hypoxia PET tracer currently in Phase 3 clinical trials (NCT06563479) for HPV-positive oropharyngeal cancer, which is designed to identify tumor hypoxia and enable radiation dose de-escalation from 70 Gray to 30 Gray for the approximately 75-80% of patients with non-hypoxic tumors. Beyond the lead asset, the pipeline includes three undisclosed candidates — JBS-005 α, β, and γ — built on a multi-isotope platform using alpha, beta, and PET-emitting radioisotopes respectively to address undisclosed oncology indications.

The company's underlying technology combines proprietary ligand chemistry with established radioisotope science, supported by an April 2026 strategic licensing agreement with Memorial Sloan Kettering Cancer Center that provides access to clinical data, research expertise, and regulatory pathway support. JBS-003's mechanistic foundation rests on the trapping of 18F-FMISO in oxygen-starved tumor tissue, a phenomenon with the deepest clinical dataset of any hypoxia tracer dating to late-1980s European use. The founding team and Scientific Advisory Board — chaired by Jason S. Lewis, Ph.D. (Emily Tow Chair in Oncology at MSK) — bring prior experience from Evergreen Theragnostics (sold to Lantheus for $1B+ in 2025), Jubilant Radiopharma, Advanced Accelerator Applications (acquired by Novartis in 2018), and MSK.

Juniper Biosciences operates a B2B enterprise go-to-market model targeting top cancer treatment institutions and academic medical centers, with planned commercialization supported by pass-through reimbursement mechanisms. The company is pre-revenue, with its first commercial launch not expected until after a target NDA filing in late 2029. It closed an oversubscribed $40 million seed financing in December 2025 led by NovaCapital, with participation from high-net-worth individuals and Club Degli Investitori members, providing capital runway for Phase 3 advancement of JBS-003 and continued pipeline buildout. No commercial customers, partnerships beyond MSK, or geographic expansion outside North America are currently disclosed.

Name

Juniper Biosciences

Legal name

Juniper Biosciences

Website

https://juniperbiosci.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Juniper Biosciences is a pre-revenue radiopharmaceutical drug developer founded in 2025 in Bridgewater, NJ, advancing JBS-003, a first-in-class 18F-FMISO hypoxia PET tracer in Phase 3 for HPV-positive oropharyngeal cancer, alongside undisclosed multi-isotope (alpha, beta, gamma) candidates targeting solid tumors.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAIAGAA

Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYHLAIAGAB

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

• Radiopharmaceutical development
• PET imaging agents
• Precision oncology diagnostics
• Targeted cancer therapeutics
• Theranostic drug development

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Radiopharmaceutical Product Sales: Revenue from sale of proprietary radiopharmaceutical diagnostic and therapeutic products to healthcare institutions upon regulatory approval. The company is in clinical development stage with no current revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Juniper Biosciences is a clinical-stage radiopharmaceutical drug development company developing proprietary diagnostic and therapeutic agents that combine targeted molecular imaging with therapeutic delivery for oncology. Its lead program, JBS-003 (18F-FMISO), is a first-in-class hypoxia PET tracer in Phase 3 development for HPV-positive oropharyngeal cancer, designed to enable precision risk-stratification and radiation dose de-escalation. The company also advances a multi-isotope pipeline of alpha, beta, and PET-emitting candidates (JBS-005 α, β, γ) across undisclosed indications.

Product overview

Juniper Biosciences is a radiopharmaceutical drug development company advancing a pipeline of radiopharmaceutical agents across multiple disease states, combining targeted diagnostics and therapeutic delivery to improve oncology outcomes. The core portfolio includes JBS-003 (F-MISO), a first-in-class hypoxia PET tracer in Phase 3 for HPV-positive oropharyngeal cancer, alongside three additional undisclosed candidates (JBS-005 α, JBS-005 β, JBS-005 γ) utilizing alpha, beta, and PET emitters respectively, collectively balancing clinically proven solutions with novel theranostics.

Differentiator

Problem solved

Functional benefit

Products and services

• JBS-003 (18F-Fluoromisonidazole / F-MISO) First-in-class 18F-fluoromisonidazole (FMISO) PET hypoxia tracer that identifies tumor hypoxia in HPV-positive oropharyngeal carcinoma, enabling precision risk-stratification and radiation dose de-escalation from 70 Gray to 30 Gray for non-hypoxic tumors. Currently in Phase 3 clinical trials for HPV-positive oropharyngeal cancer.
• JBS-005 α

Quantifiable outcome

• 67% radiation dose reduction from 70 Gray to 30 Gray for hypoxia-negative patients with comparable cure rates
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Jason S. Lewis, Ph.D.coreStrategic or Co-development Partner · 18 May 2026Appointed as inaugural Chair of Juniper Biosciences' Scientific Advisory Board. Dr. Lewis holds the Emily Tow Chair in Oncology at MSK and serves as Deputy Director of the Sloan Kettering Institute. He is a world-renowned leader in molecular imaging and radiochemistry with over 380 peer-reviewed publications. Dr. Lewis has financial interests related to Juniper Biosciences.
• Memorial Sloan Kettering Cancer Center (MSK)coreStrategic or Co-development Partner · 28 April 2026Strategic licensing agreement with MSK to accelerate development of JBS-003 (18F-fluoromisonidazole/FMISO). MSK provides clinical data, research expertise, and regulatory pathway support. MSK's Nancy Lee, MD serves as Vice Chair, Experimental Therapeutics in Department of Radiation Oncology. MSK has financial interests in Juniper Biosciences.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Lantheus Holdings: Established radiopharmaceutical leader that acquired Evergreen Theragnostics for $1B+ in 2025, where Juniper's founders previously operated. Directly comparable as a public radiopharma incumbent with diagnostic (e.g., Pylarify for PSMA PET) and therapeutic franchises and the most likely strategic acquirer.
• GE HealthCare: Diversified medical imaging and radiopharma player with established PET tracer portfolio (Vizamyl originally licensed from GE) and growing theranostic ambitions. Comparable as a large incumbent that competes in oncology PET imaging where Juniper is seeking entry.
• Novartis (Advanced Accelerator Applications): Acquired AAA in 2018 for $3.9B and commercializes Pluvicto and Lutathera, the leading therapeutic radioligands. Most relevant incumbent validating the radiopharmaceutical theranostic thesis; advisor Pietro Bubba Bello began his career at AAA, directly linking the two companies.
• Bayer (including Algeta legacy): Through its Algeta acquisition and broader radiopharma platform (Xofigo), Bayer is a major incumbent in targeted radionuclide therapy. Comparable as a global pharma developing and commercializing radiopharmaceuticals across multiple cancer indications.

Direct peers

• Curium: Private global radiopharmaceutical company providing diagnostic and therapeutic nuclear medicine products across PET, SPECT, and therapeutic isotopes. Directly comparable as a vertically integrated radiopharma player with established manufacturing and distribution infrastructure.
• Telix Pharmaceuticals: Commercial-stage radiopharma company with multiple approved PET imaging agents (Illuccix, Vizamyl) and a theranostic platform spanning diagnostics and therapeutics. Comparable to Juniper in deploying targeted imaging diagnostics to stratify oncology patients and develop companion therapeutics.
• POINT Biopharma: Radiopharmaceutical company developing targeted radioligand therapies for cancer, acquired by Eli Lilly in 2024 for ~$1.4B. Directly comparable as a clinical-to-commercial stage radiopharma platform with therapeutic focus and PSMA franchise, validating the radiopharma M&A premium.
• ITM Isotope Technologies Munich: Radiopharmaceutical company developing targeted radionuclide therapies and diagnostics for various hard-to-treat cancers, with a focus on novel theranostic pairs. Comparable as a clinical-stage platform with overlapping pipeline depth in alpha/beta emitters and diagnostics.
• Blue Earth Diagnostics (Bracco): Radiopharmaceutical diagnostics subsidiary of Bracco Imaging focused on PET imaging agents for oncology, including Axumin for prostate cancer. Comparable as a specialized radiopharma diagnostics company targeting oncology indications with novel PET tracers.

Others

• Cardinal Health (Nuclear Pharmacy): Largest US radiopharma distributor operating a national network of nuclear pharmacies serving hospitals and clinics. Adjacent comparable as the critical distribution infrastructure that Juniper will likely rely on for last-mile delivery of JBS-003 to top cancer centers.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/juniper-biosciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juniper Biosciences